Resumed Overweight X

DNLI Denali Therapeutics

Morgan Stanley

$41 $33

Initiated Buy X

DNLI Denali Therapeutics

Deutsche Bank

$31

Initiated Outperform X

DNLI Denali Therapeutics

Robert W. Baird

$31

Initiated Outperform X

DNLI Denali Therapeutics

William Blair

Upgrades Hold Buy X

DNLI Denali Therapeutics

Stifel

$37

Resumed Mkt Perform X

DNLI Denali Therapeutics

Raymond James

Downgrades Overweight Neutral X

DNLI Denali Therapeutics

Cantor Fitzgerald

Initiated Buy X

DNLI Denali Therapeutics

Citigroup

$32

Resumed Overweight X

DNLI Denali Therapeutics

JP Morgan

$28

Resumed Overweight X

DNLI Denali Therapeutics

Cantor Fitzgerald

$85 $35

Initiated Buy X

DNLI Denali Therapeutics

B. Riley Securities

$38

Initiated Outperform X

DNLI Denali Therapeutics

SVB Securities

$50

Initiated Outperform X

DNLI Denali Therapeutics

Cowen

Initiated Buy X

DNLI Denali Therapeutics

BofA Securities

$40

Upgrades Neutral Buy X

DNLI Denali Therapeutics

BTIG Research

$38

Initiated Buy X

DNLI Denali Therapeutics

Berenberg

$39

Resumed Mkt Perform X

DNLI Denali Therapeutics

Raymond James

Initiated Buy X

DNLI Denali Therapeutics

UBS

$70

Reiterated Buy X

DNLI Denali Therapeutics

H.C. Wainwright

$80 $95

Upgrades Neutral Overweight X

DNLI Denali Therapeutics

Cantor Fitzgerald

$105

Initiated Buy X

DNLI Denali Therapeutics

BTIG Research

$30

Initiated Buy X

DNLI Denali Therapeutics

H.C. Wainwright

$28

Initiated Overweight X

DNLI Denali Therapeutics

Cantor Fitzgerald

$25

Initiated Buy X

DNLI Denali Therapeutics

Janney

Downgrades Outperform In-line X

DNLI Denali Therapeutics

Evercore ISI

DNLI  Denali Therapeutics Inc.

Denali Therapeutics Inc., is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS). The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease. The Company has selected approximately three specific pathways that are implicated as triggers or effectors of neurodegeneration, including degenogenes (genes that cause neurodegenerative disease when mutated), defective intracellular trafficking, glial dysfunction and axon degeneration.